News – Page 1051 – Endpoints News

The Trump effect: PwC report says the FDA has slammed the brakes on significant new drug regulations

8 years ago

Hit by an expected EMA rejection, Puma plans to appeal negative opinion on neratinib

8 years ago

Shionogi, Roche get their first approval for the next big thing in fighting the flu

8 years ago

Bellicum outlines a few quick steps the FDA wants before lifting its hold on lead cell therapy, shares rise

8 years ago

Evelo Bio raises $47.5M for I/O work; Vertex gets started on a fast pivotal effort for triple CF combo

8 years ago

Stem cell co Mesoblast reports PhIII trial success in children with GVHD

8 years ago

Fast ex-Flexus team takes Arcus to a quick $100M IPO to advance I/O pipeline

8 years ago

Bristol-Myers axes 107 more staffers as it completes an R&D overhaul

8 years ago

All in: Gilead maps a $3.15B gene editing alliance with Sangamo for off-the-shelf CAR-T drugs

8 years ago

Abandoned by J&J, faded hep C star Achillion axes staff and maps path to PhII readouts

8 years ago

In a turf war with Eli Lilly, Novo Nordisk steps off with positive PhIII for its challenging oral GLP-1 drug

8 years ago

Is NYC a biotech hub? Gut-brain startup Kallyope, equipped with $66M in new money, says yes

8 years ago

GW Pharma shares dented after cannabinoid drug fails a PhIIa study on focal seizures

8 years ago

Top Pfizer research exec John Davis joins migration to biotech, lands at Magenta as CMO

8 years ago

Senior R&D exec Sue Dillon jumps ship at J&J, launches mystery biotech startup Aro with Centyrins tech

8 years ago

Ex-HHS Secretary Tommy Thompson adds another biotech to his resume; Medigene OK'd for first TCR clinical trial

8 years ago

On a journey to find and fuel new biotech ventures, Arix adds France's Ipsen to its network of partners

8 years ago

AbbVie rolls up another big win for elagolix as the prospective blockbuster sweeps endpoints in latest PhIII

8 years ago

The good, the bad and the ugly for the top 15 spenders in the global drug R&D business: 2018

8 years ago

The I/O 2.0-combo tech race is on: Merck bags oncolytics player Viralytics in $394M buyout

8 years ago

Takeda commits to a $230M package to seal blockbuster neurological R&D deal with Wave Life Sciences

8 years ago

Acorda gets a badly needed PDUFA date with the FDA on Parkinson's drug; Takeda signs neurological collaboration with ...

8 years ago

Amid buzz around a short seller’s FBI visit, MiMedx stock craters following internal investigation

8 years ago

AstraZeneca hauls kidney disease drug into the clinic after handing Ionis $30M in cash, $300M in milestones

8 years ago

First page Previous page 1048 1049 105010511052 1053 1054 Next page Last page